Optimize Novel Pathway Targeting, Assay Validation & Clinical Translation to Drive Complement Inhibition for Rare & Common Diseases
The complement system plays a key role in innate immunity but is also known to drive pathogenesis and contribute to the inflammatory profile of an increasing number of diseases. The success of eculizumab in the treatment of PNH and Ahus has validated this system as a specific therapeutic target, and now it is evident that an explosion of complement therapies are in development.
The Complement-based Drug Development Summit remains to be the only industry dedicated meeting that brings you the most up to date clinical and commercial developments utilizing complement inhibitors in rare and common disease indications.
The 2020 conference programme will bring together a wealth of knowledge into the complexities of the role of complement biology in disease and the therapeutic strategies which are being employed to yield clinical efficacy.
Join 150+ senior level complement experts from pharma, biotech and leading research institutions who are all working towards the same goal; to achieve clinical approval of effective complement inhibitors in rare and common disease indications.
Download the event guide to learn what our X+ speakers will be addressing.
"This was a well-balanced mix of speakers representing early and late drug development efforts and approaches that have worked and ones that have failed, we often only hear the success stories, but one can learn maybe even more from the failures."
"The Complement-based Drug Development regrouped the majority of the key players of the Pharmaceutical Industry in the complement field. It is priceless to be able to interact with each other at this level of Science"
"As an academic researcher, I had a rare and valuable experience to be exposed to the way industry leaders approach some challenging topics, assess various sources of data and take scientific and business decisions. I learned a lot and my perspective has been enriched"
“This unique forum really is one of those “don’t miss” events, which is why I agreed to speak this year. I’m very impressed with the agenda connecting participants to a world-class speaker faculty on key areas from; developing translational biomarkers to discussing latest clinical data. Looking forward to meet and discuss with the experts in this exciting field”.
Muneto Mogi, Executive Director, Global Discovery Chemistry, Novartis